Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
N Engl J Med. 2013 Sep 19;369(12):1095-105. doi: 10.1056/NEJMoa1301969.
Colonoscopy and sigmoidoscopy provide protection against colorectal cancer, but the magnitude and duration of protection, particularly against cancer of the proximal colon, remain uncertain.
We examined the association of the use of lower endoscopy (updated biennially from 1988 through 2008) with colorectal-cancer incidence (through June 2010) and colorectal-cancer mortality (through June 2012) among participants in the Nurses' Health Study and the Health Professionals Follow-up Study.
Among 88,902 participants followed over a period of 22 years, we documented 1815 incident colorectal cancers and 474 deaths from colorectal cancer. With endoscopy as compared with no endoscopy, multivariate hazard ratios for colorectal cancer were 0.57 (95% confidence interval [CI], 0.45 to 0.72) after polypectomy, 0.60 (95% CI, 0.53 to 0.68) after negative sigmoidoscopy, and 0.44 (95% CI, 0.38 to 0.52) after negative colonoscopy. Negative colonoscopy was associated with a reduced incidence of proximal colon cancer (multivariate hazard ratio, 0.73; 95% CI, 0.57 to 0.92). Multivariate hazard ratios for death from colorectal cancer were 0.59 (95% CI, 0.45 to 0.76) after screening sigmoidoscopy and 0.32 (95% CI, 0.24 to 0.45) after screening colonoscopy. Reduced mortality from proximal colon cancer was observed after screening colonoscopy (multivariate hazard ratio, 0.47; 95% CI, 0.29 to 0.76) but not after sigmoidoscopy. As compared with colorectal cancers diagnosed in patients more than 5 years after colonoscopy or without any prior endoscopy, those diagnosed in patients within 5 years after colonoscopy were more likely to be characterized by the CpG island methylator phenotype (CIMP) (multivariate odds ratio, 2.19; 95% CI, 1.14 to 4.21) and microsatellite instability (multivariate odds ratio, 2.10; 95% CI, 1.10 to 4.02).
Colonoscopy and sigmoidoscopy were associated with a reduced incidence of cancer of the distal colorectum; colonoscopy was also associated with a modest reduction in the incidence of proximal colon cancer. Screening colonoscopy and sigmoidoscopy were associated with reduced colorectal-cancer mortality; only colonoscopy was associated with reduced mortality from proximal colon cancer. Colorectal cancer diagnosed within 5 years after colonoscopy was more likely than cancer diagnosed after that period or without prior endoscopy to have CIMP and microsatellite instability. (Funded by the National Institutes of Health and others.).
结肠镜检查和乙状结肠镜检查可预防结直肠癌,但预防的程度和持续时间,特别是对近端结肠癌的预防效果,仍不确定。
我们分析了参加护士健康研究和健康专业人员随访研究的参与者中,使用下消化道内镜(从 1988 年开始每两年更新一次,至 2008 年)与结直肠癌发病率(至 2010 年 6 月)和结直肠癌死亡率(至 2012 年 6 月)之间的关系。
在随访 22 年期间,我们对 88902 名参与者进行了研究,共记录了 1815 例结直肠癌发病病例和 474 例结直肠癌死亡病例。与未行内镜检查相比,息肉切除后,结直肠癌的多变量风险比为 0.57(95%置信区间 [CI],0.45 至 0.72);乙状结肠镜检查阴性后为 0.60(95%CI,0.53 至 0.68);结肠镜检查阴性后为 0.44(95%CI,0.38 至 0.52)。结肠镜检查阴性与近端结肠癌发病率降低相关(多变量风险比,0.73;95%CI,0.57 至 0.92)。筛查乙状结肠镜检查后结直肠癌死亡的多变量风险比为 0.59(95%CI,0.45 至 0.76),而筛查结肠镜检查后为 0.32(95%CI,0.24 至 0.45)。筛查结肠镜检查可降低近端结肠癌的死亡率(多变量风险比,0.47;95%CI,0.29 至 0.76),但乙状结肠镜检查无此作用。与结肠镜检查后 5 年以上或无任何先前内镜检查的结直肠癌患者相比,结肠镜检查后 5 年内诊断出的结直肠癌更可能具有 CpG 岛甲基化表型(CIMP)(多变量比值比,2.19;95%CI,1.14 至 4.21)和微卫星不稳定性(多变量比值比,2.10;95%CI,1.10 至 4.02)。
结肠镜检查和乙状结肠镜检查与结直肠癌远端发病率降低相关;结肠镜检查还与近端结肠癌发病率的适度降低相关。筛查结肠镜检查和乙状结肠镜检查与结直肠癌死亡率降低相关;只有结肠镜检查与降低近端结肠癌死亡率相关。结肠镜检查后 5 年内诊断出的结直肠癌比该时间后或无先前内镜检查诊断出的结直肠癌更可能具有 CIMP 和微卫星不稳定性。(由美国国立卫生研究院和其他机构资助)。